UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 24, 2013
SHENGTAI PHARMACEUTICAL, INC.
(Exact name of registrant as specified in its charter)
Delaware (State or other jurisdiction of incorporation) | 000-51312 (Commission File Number) | 54-2155579 (IRS Employer Identification No.) |
Changda Road East Development District, Changle County Shandong, PRC (Address of principal executive offices) | 262400 (Zip Code) |
Registrant’s telephone number, including area code:011-86-536-2188831
Copies to:
Benjamin Tan, Esq.
Sichenzia Ross Friedman Ference LLP
61 Broadway, 32 Floor
New York, New York 10006
Phone: (212) 930-9700
Fax: (212) 930-9725
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 Other Events.
On April 17, 2012, Shengtai Pharmaceutical, Inc., a Delaware corporation (the “Company”), announced that its Board of Directors had received a preliminary, non-binding proposal from its Chairman and Chief Executive Officer, Mr. Qingtai Liu ("Mr. Liu"), which stated that Mr. Liu intends to acquire all the outstanding shares of the Company's common stock not currently owned by him and his affiliates in a going private transaction at a proposed price of $1.65 per share in cash (the “Proposal”).
On July 24, 2013, the Company received a letter from Mr. Liu informing it that because he had been unsuccessful in obtaining financing to fund the acquisition of all the outstanding shares of common stock of the Company not currently owned by him and his affiliates, he had decided to withdraw the Proposal immediately and would file an amendment to the Schedule 13D/A previously filed on March 25, 2013.
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| SHENGTAI PHARMACEUTICAL, INC. | |
| Dated: July 30, 2013 | |
| By:/s/Qingtai Liu | |
| Name: Qingtai Liu | |
| Title: Chief Executive Officer |
